Last reviewed 2026-04-23 · How we verify

Delayed Maintenance treatment

This drug targets the PD-1 receptor to suppress cancer cell growth.

This drug targets the PD-1 receptor to suppress cancer cell growth. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.

At a glance

Mechanism of action

By binding to the PD-1 receptor, the drug prevents cancer cells from receiving signals that promote their growth and survival. This leads to an increase in the body's immune response against cancer cells, ultimately resulting in their destruction.

Approved indications

• Non-small cell lung cancer, PD-L1 positive
• Head and neck squamous cell carcinoma

Common side effects

• Pneumonitis
• Hypothyroidism
• Hyperthyroidism
• Diarrhea
• Fatigue

Key clinical trials

• Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer (PHASE3)
• Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung (PHASE2, PHASE3)
• A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia (PHASE3)
• A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old (PHASE2)
• Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma (PHASE1)
• Testing a Novel Data-to-Suppression (D2S) Intervention Strategy in the Ryan White HIV/AIDS Program (NA)
• Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL) (PHASE3)
• Multicontext Approach for Cognitive Function in Parkinson Disease (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.